New chemotherapy options for the treatment of malignant gliomas

Anti-Cancer Drugs

Volumn 18, Issue 6, 2007, Pages 621-632

  Soffietti, Riccardo ^a   Rudà, Roberta ^a   Trevisan, Elisa ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

Cytostatic compounds; Cytotoxic drugs; Glioblastoma; O6 methylguanine methyltransferase; Targeted therapies; Temozolomide

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CC 5103; CELECOXIB; CILENGITIDE; CISPLATIN; ENZASTAURIN; EPIDERMAL GROWTH FACTOR; ERLOTINIB; FOTEMUSTINE; GEFITINIB; HYDROXYUREA; IMATINIB; IRINOTECAN; ISOTRETINOIN; LENALIDOMIDE; LOMUSTINE; LONAFARNIB; MARIMASTAT; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROCARBAZINE; R 111577; RETINOID; ROFECOXIB; TAMOXIFEN; TEMOZOLOMIDE; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTHRALGIA; BRAIN INFECTION; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CEREBROSPINAL FLUID FISTULA; CLINICAL TRIAL; CONSTIPATION; CYTOSTASIS; CYTOTOXICITY; DNA REPAIR; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; FACTORIAL DESIGN; GLIOBLASTOMA; HEALING IMPAIRMENT; HUMAN; METHYLATION; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; PATIENT CARE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; TENDON INJURY; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DNA REPAIR; GLIOMA; HUMANS;

EID: 34548354957     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32801476fd     Document Type: Review

References (151)

1. Fetell MR, Grossman SA, Fisher JD, Erlanger B, Rowinsky E, Stockel J, et al. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New approaches to brain tumor therapy central nervous system consortium. J Clin Oncol 1997; 15:3121-3128.
2. Gilbert MR, Supko JG, Batchelor T, Lesser G, Fisher JD, Piantadosi S, et al. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 2003; 9:2940-2949.
3. Walker MD, Alexander E, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J Neurosurg 1978; 49:333-343.
4. Walker MD, Green SB, Byar DP, Alexander E, Batzdorf U, Brooks WH, et al. Randomized comparison of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303:1323-1329.
5. The Medical Research Council Brain Tumour Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 2001; 19:509-518.
6. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 1990; 18:321-324.
7. Prados MD, Scott C, Curran WJ Jr, Nelson DF, Leibel S, Kramer S. Procarbazine, lomustine and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of Radiation Therapy Oncology Group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol 1999; 17:3389-3395.
8. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993; 71:2585-2597.
9. Stewart LA. Chemotherapy in adult high grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 2002; 359:1011-1018.
10. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group. Lancet 1995; 345:1008-1012.
11. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R,Warnke PC, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 2003; 5:79-88.
12. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E, On behalf of the Executive Committee of the Gliadel® Study Group 2006. Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir 2006; 148:269-275.
13. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997; 23:35-61.
14. Yung WKA, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999; 17:2762-2771.
15. Yung WKA, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al. A phase II study of temozolomide versus procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83:588-593.
16. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001; 12:259-266.
17. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999; 17:2572-2578.
18. Wedge SR, Porteous JK, Glaser MG, Marcus K, Newlands ES. In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 1997; 8:92-97.
19. Van Rijn J, Heimans JJ, Van den Berg J, Van der Valk P, Slotman BJ. Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 2000; 47:779-784.
20. Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998; 58:4363-4367.
21. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002; 20:1375-1382.
22. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-996.
23. Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 2005; 6:937-944.
24. DeAngelis LM. Chemotherapy for brain tumors: -a new beginning. N Engl J Med 2005; 352:1036-1038.
25. Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma. J Clin Oncol 1998; 16:3851-3857.
26. Gilbert MR, Friedman HS, Kuttesch JF, Prados MD, Olson JJ, Reaman GH, et al. A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-oncol 2002; 4:261-267.
27. Brada M, Ashley S, Dowe A, Gonsalves A, Huchet A, Pesce G, et al. Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide. Ann Oncol 2005; 16:942-949.
28. Bredel M. Anticancer drug resistance in primary human brain tumors. Brain Res Brain Res Rev 2001; 35:161-204.
29. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005; 23:2411-2422.
30. 6-alkylating agents in human glioblastomas. J Clin Oncol 2006; 24:274-287.
31. Jaeckle KA, Eyre HJ, Townsend JJ, Schulman S, Knudson HM, Belanich M, et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 1998; 16:3310-3315.
32. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999; 59:793-797.
33. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61:3225-3229.
34. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343:1350-1354.
35. 6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 2003; 9:1461-1468.
36. 6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3- nitrosourea-based chemotherapy. Neurosurgery 2004; 54:349-357.
37. Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L, et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004; 10:4933-4938.
38. 6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 10:1871-1874.
39. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N,Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352:997-1003.
40. Leuraud P, Taillandier L, Medioni J, Aguirre-Cruz L, Crinière E, Marie Y, et al. Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations. Cancer Res 2004; 64:4648-4653.
41. Grombacher T, Mitra S, Kaina B. Induction of the alkyltransferase (MGMT) gene by DNA damaging agents and the glucocorticoid dexamethasone and comparison with the response of base excision repair genes. Carcinogenesis 1996; 17:2329-2336.
42. Liu L, Markowitz S, Gerson SL. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res 1996; 56:5375-5379.
43. Taverna P, Liu L, Hanson AJ, Monks A, Gerson SL. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother Pharmacol 2000; 46:507-516.
44. Chang SM, Parney IF, Huang W, Anderson FA Jr, Asher AL, Bernstein M, et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA 2005; 293:557-564.
45. Cairncross G, Seiferheld W, Shaw E, Jenkins R, Scheithauer B, Brachman D, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006; 24:2707-2714.
46. Van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Berens HJ, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas: a randomized European Organization for Research and Treatment of Cancer Phase III Trial. J Clin Oncol 2006; 24:2715-2722.
47. Park N, Golden G, Meldorf M. PROLONG (prospective look at outcomes nationally with GLIADEL): interim report on the malignant glioma experience. Proc Am Ass Neurol Surg 2004; 15:83.
48. Kleinberg LR, Weingart J, Burger P, Carson K, Grossman SA, Li K, et al. Clinical course and pathologic findings after gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management. Cancer Invest 2004; 22:1-9.
49. Olivi A, Grossman SA, Tatter S, Barker F, Judy K, Olsen J, et al. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. J Clin Oncol 2003; 21:1845-1849.
50. Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 1998; 88:1-10.
51. Scott JN, Rewcastle NB, Brasher PM, Fulton D, MacKinnon JA, Hamilton M, et al.Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 1999; 46:183-188.
52. Senger D, Cairncross JG, Forsyth PA. Long-term survivors of glioblastoma: statistical aberration or important unrecognized molecular subtype? Cancer J 2003; 9:214-221.
53. Ino Y, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Jhung S, et al. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg 2000; 92:983-990.
54. Burton EC, Lamborn KR, Forsyth P, Scott J, O'Campo J, Uyehara-Lock J, et al. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res 2002; 8:180-187.
55. Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, Berger MS, et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 2001; 61:1122-1128.
56. Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer-Puttlitz B, et al. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 2002; 61:321-328.
57. Houillier C, Lejeune J, Benouaich-Amiel A, Laigle-Donadey F, Criniere E, Mokhtari K, et al. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 2006; 106:2218-2223.
58. 6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 1994; 69:452-456.
59. Payne MJ, Pratap SE, Middleton MR. Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling. Crit Rev Oncol Hematol 2005; 53:241-252.
60. Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003; 88:1004-1011.
61. Wick W, Steinbach JP, Kuker WM, Dichgans J, Bamberg M, Weller M. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 2004; 62:2113-2115.
62. Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 2005; 23:2372-2377.
63. Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neurooncol 2002; 4:39-43.
64. + lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004; 22:610-616.
65. Vera K, Djafari L, Faivre S, Guillamo JS, Djazouli K, Osorio M, et al. Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. Ann Oncol 2004; 15:161-171.
66. Wick W, Weller M. How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. J Clin Oncol 2005; 23:4235-4236.
67. Tosoni A, Cavallo G, Ermani M, Scopece L, Franceschi E, Ghimenton C, et al. Is protracted low-dose temozolomide feasible in glioma patients? Neurology 2006; 66:427-429.
68. Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE. Salvage temozolomide for prior temozolomide responders. Cancer 2005; 104:2473-2476.
69. Berrocal A, Perez-Segura P, Gil M, Balana C, Yaya-Yur R, Yaya-Tur R, et al. Phase II study of extended schedule temozolomide in refractory gliomas. Proc Am Soc Clin Oncol 2006; 24:62s.
70. Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, et al. Phase II trial of carmustine plus O6-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 2002; 20:2277-2283.
71. Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin Cancer Res 2006; 12:328-331.
72. Curtin NJ, Wang LZ, Yiakouvaki A, Kyle S, Arris CA, Canan-Koch S, et al. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res 2004; 10:881-889.
73. Tentori L, Leonetti C, Scarsella M, D'Amati G, Vergati M, Portarena I, et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 2003; 9:5370-5379.
74. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004; 96:56-67.
75. Plummer R, Evans J, Steven N, Middleton M, Wilson R, Snow K, et al. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). Proc Am Soc Clin Oncol 2006; 24:456s.
76. 6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Ann Oncol 1999; 10:831-838.
77. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002; 20:2388-2399.
78. Plowman J, Waud WR, Koutsoukos AD, Rubinstein LV, Moore TD, Grever MR. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 1994; 54:3793-3799.
79. Schold SC Jr, Kuhn JG, Chang SM, Bosik ME, Robins HI, Mehta MP, et al. A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study. Neuro-oncol 2000; 2:34-39.
80. Chang SM, Prados MD, Yung WK, Fine H, Junck L, Greenberg H, et al. Phase II study of neoadjuvant 1,3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. Cancer 2004; 100:1712-1716.
81. Prados MD, Yung WK, Fine HA, Greenberg HS, Junck L, Chang S, et al. Phase II study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium Study. Neuro-oncol 2004; 6:33-37.
82. Hammond LA, Eckardt JR, Kuhn JG, Gerson SL, Johnson T, Smith L, et al. A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. Clin Cancer Res 2004; 10:1645-1656.
83. Barrié M, Couprie C, Dufour H, Figarella-Branger D, Muracciole X, Hoang-Xuan K, et al. Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. Ann Oncol 2005; 16:1177-1184.
84. Gururangan S, Cokgor L, Rich JN, Edwards S, Affronti ML, Quinn JA, et al. Phase I study of gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-oncol 2001; 3:246-250.
85. Larocca RV, Vitaz TW, Morassutti DJ. A phase II study of radiation with concomitant and then sequential temozolomide (TMZ) in patients (pts) with newly diagnosed supratentorial high grade malignant glioma (MG) who have undergone surgery with carmustine (BCNU) wafer insertion. Proc Am Soc Clin Oncol 2005; 23:1547.
86. Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann RD, et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 2006; 24:4412-4417.
87. 6-alkylguanine- DNA alkyltransferase activity. J Neurooncol 2001; 52:149-156.
88. Brandes AA, Turazzi S, Basso U, Pasetto LM, Guglielmi B, Volpin L, et al. A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme. Neurology 2002; 58:1759-1764.
89. Silvani A, Eoli M, Salmaggi A, Lamperti E, Maccagnano E, Broggi G, et al. Phase II trial of cisplatin plus temozolomide in recurrent and progressive malignant glioma patients. J Neurooncol 2004; 66:203-208.
90. Grossman SA, Wharam M, Sheidler V, Kleinberg L, Zeltzman M, Yue N, et al. Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. J Clin Oncol 1997; 15:2596-2603.
91. Grossman SA, O'Neill A, Grunnet M, Mehta M, Pearlman JL, Wagner H, et al. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 2003; 21:1485-1491.
92. Hare CB, Elion GB, Houghton PJ, Houghton JA, Keir S, Marcelli SL, et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 1997; 39:187-191.
93. Friedman HS, PetrosWP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999; 17:1516-1525.
94. Buckner JC, Reid JM, Wright K, Kaufmann SH, Erlichman C, Ames M, et al. Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group. Cancer 2003; 97:2352-2358.
95. Raymond E, Fabbro M, Boige V, Rixe O, Frenay M, Vassal G, et al. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann Oncol 2003; 14:603-614.
96. Batchelor TT, Gilbert MR, Supko JG, Carson KA, Nabors LB, Grossman SA, et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro-oncol 2004; 6:21-27.
97. Castellino RC, Elion GB, Keir ST, Houghton PJ, Johnson SP, Bigner DD, et al. Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. Cancer Chemother Pharmacol 2000; 45:345-349.
98. Reardon DA, Quinn JA, Rich JN, Gururangan S, Vredenburgh J, Sampson JH, et al. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro-oncol 2004; 6:134-144.
99. Storm PB, Renard VM, Moriarity JL, Tyler B, Wilentz RE, Brem H, et al. Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma. Cancer Chemother Pharmacol 2004; 54:361-367.
100. Patel VJ, Elion GB, Houghton PJ, Keir S, Pegg AE, Johnson SP, et al. Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin Cancer Res 2000; 6:4154-4157.
101. Reardon DA, Quinn JA, Rich JN, Desjardins A, Vredenburgh J, Gururangan S, et al. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer 2005; 104:1478-1486.
102. Caraglia M, Addeo R, Costanzo R, Montella L, Faiola V, Marra M, et al. Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. Cancer Chemother Pharmacol 2006; 57:34-39.
103. Hau P, Fabel K, Baumgart U, Rummele P, Grauer O, Bock A, et al. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 2004; 100:1199-1207.
104. Drappatz J, Wen PY. Non-cytotoxic drugs as potential treatments for gliomas. Curr Opin Neurol 2004; 17:663-673.
105. Fine HA,Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 2003; 21:2299-2304.
106. Baumann F, Bjeljac M, Kollias SS, Baumert BG, Brandner S, Rousson V, et al. Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme. J Neurooncol 2004; 67:191-200.
107. Chang SM, Lamborn KR, Malec M, Larson D, Wara W, Sneed P, et al. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2004; 60:353-357.
108. Wick W, Wick A, Schulz JB, Dichgans J, Rodemann HP, Weller M. Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res 2002; 62:1915-1919.
109. Joki T, Heese O, Nikas DC, Bello L, Zhang J, Kraeft SK, et al. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res 2000; 60:4926-4931.
110. Reardon DA, Quinn JA, Vredenburgh J, Rich JN, Gururangan S, Badruddoja M, et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 2005; 103:329-338.
111. Tuettenberg J, Grobholz R, Korn T,Wenz F, Erber R, Vajkoczy P. Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol 2005; 131:31-40.
112. Pannullo SC, Burton J, Serventi J, Stieg G, Subramanian H, Elsoueidi R, et al. Phase I/II trial of twice-daily temozolomide and celecoxib for treatment of relapsed malignant glioma: final data. Proc Am Soc Clin Oncol 2006; 24:62s.
113. Couldwell WT, Hinton DR, Surnock AA, DeGiorgio CM, Weiner LP, Apuzzo ML, et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 1996; 2:619-622.
114. Mastronardi L, Puzzilli F, Couldwell WT, Farah JO, Lunardi P. Tamoxifen and carboplatin combinational treatment of high-grade gliomas. Results of a clinical trial on newly diagnosed patients. J Neurooncol 1998; 38:59-68.
115. Brandes AA, Ermani M, Turazzi S, Scelzi E, Berti F, Amista P, et al. Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. J Clin Oncol 1999; 17:645-650.
116. Chen TC, Su S, Fry D, Liebes L. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma. Cancer 2003; 97:2363-2373.
117. Spence AM, Peterson RA, Scharnorst JD, Silbergeld DL, Rostomily RC. Phase II study of concurrent continous temozolomide (TMZ) and tamoxifen (TMX) for recurrent malignant astrocytic gliomas. J Neurooncol 2004; 70:91-95.
118. Fine HA, Kim L, Royce C, et al. Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. In: Proceedings of the American Society of Clinical Oncology. Orlando, May 13-17, 2005. Abstract 1511.
119. Tonn JC, Kerkau S, Hanke A, Bouterfa H, Mueller JG, Wagner S, et al. Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. Int J Cancer 1999; 80:764-772.
120. Levin VA, Phuphanich S, Yung WK, Forsyth PA, Maestro RD, Perry JR, et al. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol 2006; 78:295-302.
121. Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 2002; 20:1383-1388.
122. Groves MD, Puduvalli VK, Conrad CA, Gilbert MR, Yung WK, Jaeckle K, et al. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol 2006; 80:83-90.
123. Jaeckle KA, Hess KR, Yung WK, Greenberg H, Fine H, Schiff D, et al. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 2003; 21:2305-2311.
124. Butowski N, Prados MD, Lamborn KR, Larson DA, Sneed PK,Wara WM, et al. A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int J Radiat Oncol Biol Phys 2005; 61:1454-1459.
125. Butowski N, Chang SM. Small molecule and monoclonal antibody therapies in neurooncology. Cancer Control 2005; 12:116-124.
126. Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 2006; 24:1253-1265.
127. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345.
128. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
129. Chakravarti A, Dicker A, Mehta M. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int J Radiat Oncol Biol Phys 2004; 58:927-931.
130. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004; 22:133-142.
131. Mellinghoff IK,Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353:2012-2024.
132. Haas-Kogan DA, Prados MD, Tihan T, Eberha rd DA, Jelluma N, Arvold ND, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005; 97:880-887.
133. Peereboom DM, Brewer C, Stevens GHJ, et al. Phase II trial of erlotinib with temozolomide and concurrent radiation therapy post-operatively in patients with newly diagnosed glioblastoma multiforme. Neuro-oncol 2005; 6:379.
134. Prados MD, Lamborn KR, Chang S, Burton E, Butowski N, Malec M, et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro-oncol 2006; 8:67-78.
135. Wen PY, Kesari S. Malignant gliomas. Curr Neurol Neurosci Rep 2004; 4:218-227.
136. Raymond E, Brandes A, Van Osterom A, Dittrich C, Fumoleau P, Coudert B. Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: an EORTC NCCG/BTG Intergroup study. Proc Am Soc Clin Oncol 2004; 22:107s.
137. Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol 2005; 16:1702-1708.
138. Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 2005; 23:9359-9368.
139. Goldbrunner RH, Bendszus M, Wood J, Kiderlen M, Sasaki M, Tonn JC. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery 2004; 55:426-432.
140. Reardon D, Friedman H, Yung WKA. A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol 2004; 23:110.
141. Vredenburgh JJ, Desjardins A, Herndon JE II, Quinn J, Rich J, Sathornsumetee A, et al. Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant
142. Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 2006; 24:3651-3656.
143. Gilbert MR, Hess KR, Gaupp P, et al. A phase I study of temozolomide and farnesyltransferase inhibitor, tipifarnib in recurrent glioblastoma: a dose and schedule intensive regimen. Neuro-oncol 2004; 6:375.
144. Doherty L, Gigas DC, Kesari S, Drappatz J, Kim R, Zimmerman J, et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 2006; 67:156-158.
145. Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM. Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res 2002; 8:2725-2734.
146. Xu GW, Mymryk JS, Cairncross JG. Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide. Int J Cancer 2005; 116:187-192.
147. 6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 2006; 96:766-776.
148. Curran WJ Jr, Scott CB, Horton J, Nelson JS,Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:690-691.
149. Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 1998; 40:51-55.
150. Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 2006; 24:2563-2569.
151. Lang FF, Gilbert MR, Puduvalli VK,Weinberg J, Levin VA, Yung WK, et al. Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies. Neuro-oncol 2002; 4:268-277.